EGFR + NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in EGFR + NSCLC research. Learn more about our innovative pipeline today! @ EGFR + NSCLC Pipeline Outlook
Key Takeaways from the EGFR + NSCLC Pipeline Report
In July 2025, ETOP IBCSG Partners Foundation announced a primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial.
In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor (HER2) mutations. The study drug, BH-30643 capsules, will be self-administered by mouth twice daily in 21-day cycles.
In June 2025, Merck Sharp & Dohme LLC organized a study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).
DelveInsight's EGFR + NSCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for EGFR + NSCLC treatment.
The leading EGFR + NSCLC Companies such as Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
Promising EGFR+NSCLC Pipeline Therapies such as IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others.
Stay informed about the cutting-edge advancements in EGFR + NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ EGFR + NSCLC Clinical Trials Assessment
EGFR + NSCLC Emerging Drugs Profile
CLN-081 is a novel irreversible Epidermal Growth Factor Receptor (EFGR) inhibitor. It is administered through oral route, and is developed by Cullinan Oncology. The drug is being developed in association with Taiho Pharmaceuticals. The drug is currently being investigated in the Phase III stage of development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC).
BPI-361175: Betta Pharmaceuticals
BPI-361175 is a novel, oral, highly potent and selective 4th generation EGFR inhibitor developed by Betta Pharmaceutical Co., Ltd. The new chemical entity targets EGFR C797S mutation and other EGFR related mutations that are resistant to 3rd generation EGFR TKI in non-small cell lung cancer (NSCLC) and other solid tumors. It shows excellent inhibitory effect and selectivity in vitro assay and exhibits significant anti-tumor activity in a variety of xenograft models harboring EGFR C797S or other related mutations. The IND application of BPI-361175 has been approved by NMPA. Currently, the drug is the Phase I/II stage of its development for the treatment of Non-small Cell Lung Cancer.
G1T38: G1 Therapeutics
G1T38 is an investigational, oral CDK4/6 inhibitor designed to be used along with other targeted therapies for various oncology indications. G1 Therapeutics has entered a clinical trial collaboration to assess its G1T38 in combination with AstraZeneca's Tagrisso (osimertinib) in a Phase Ib/II clinical trial to treat patients suffering from EGFR mutation-positive non-small cell lung cancer (NSCLC). Currently, the drug is being evaluated in the Phase I/II stage in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer.
JANX008: Janux Therapeutics
JANX008, is a TRACTr that targets Epidermal Growth Factor Receptor (EGFR), and is being developed by Janux Therapeutics for the treatment of various solid tumors including non-small cell lung cancer. According to preclinical studies, JANX008 showed potent cleavage dependent anti-tumor activity, with limited toxicities in healthy tissues or CRS. JANX008, is currently being evaluated in phase I clinical trial for the treatment of various solid tumors.
The EGFR + NSCLC Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of EGFR + NSCLC with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR + NSCLC Treatment.
EGFR + NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
EGFR + NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR + NSCLC market.
Learn more about EGFR + NSCLC Drugs opportunities in our groundbreaking EGFR + NSCLC research and development projects @ EGFR + NSCLC Unmet Needs
EGFR + NSCLC Companies
Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
EGFR + NSCLC Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Discover the latest advancements in EGFR + NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ EGFR + NSCLC Market Drivers and Barriers, and Future Perspectives
Scope of the EGFR + NSCLC Pipeline Report
Coverage- Global
EGFR + NSCLC Companies- Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
EGFR+NSCLC Pipeline Therapies- IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others.
EGFR + NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
EGFR + NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of EGFR + NSCLC Pipeline on our website @ EGFR + NSCLC Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
EGFR Non-Small Cell Lung Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
EGFR Non-Small Cell Lung Cancer – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
CLN-081: Cullinan Oncology
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
BPI-361175: Betta Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Market Drivers and Barriers
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Future Perspectives and Conclusion
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Analyst Views
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
Eaton declares quarterly dividend payable August 22, 2025
The Board of Directors of intelligent power management company Eaton (NYSE:ETN) today declared a quarterly dividend of $1.04 per ordinary share. The dividend is payable August 22, 2025, to shareholders of record at the close of business on August 7, 2025. Eaton has paid dividends on its shares every year since 1923. Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we're helping to solve the world's most urgent power management challenges and building a more sustainable society for people today and generations to come. Founded in 1911, Eaton has continuously evolved to meet the changing and expanding needs of our stakeholders. With revenues of nearly $25 billion in 2024, the company serves customers in more than 160 countries. For more information, visit Follow us on LinkedIn.
Globe and Mail
an hour ago
- Globe and Mail
SEGG Media (NASDAQ: SEGG, LTRYW) Taps IBN to Lead Corporate Communications
SEGG Media (NASDAQ: SEGG, LTRYW), a technology company focused on the convergence of sports, entertainment and gaming, has engaged IBN to lead its corporate communications. The move follows SEGG Media's rebrand and expansion across three verticals: Entertainment and With a $100 million financing facility and acquisitions in progress, SEGG Media is advancing a multi-vertical strategy to unify fan experiences across digital platforms. IBN will support the effort through its broad investor-focused media network and communications tools. To view the full press release, visit About SEGG Media Corporation SEGG Media is a global sports, entertainment and gaming group operating digital assets such as and Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love. NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications
Globe and Mail
an hour ago
- Globe and Mail
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
Thermo Fisher Scientific Inc. 's TMO second-quarter 2025 adjusted earnings per share (EPS) of $5.36 beat the Zacks Consensus Estimate by 2.7%. However, the figure decreased 0.2% year over year. The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs. GAAP EPS was $4.28, up 6% on a year-over-year basis. Following the earnings announcement, shares of TMO rose 7.7% in pre-market trading today. TMO's Q2 Revenues in Detail Revenues in the quarter increased 2.9% year over year to $10.85 billion. Moreover, the top line surpassed the Zacks Consensus Estimate by 1.9%. Organic revenues in the reported quarter increased 2% year over year. Thermo Fisher's Segmental Analysis Thermo Fisher operates under four business segments, as discussed below: Life Sciences Solutions Revenues in the Life Sciences Solutions segment (23% of total revenues) increased 6.1% year over year to $2.50 billion. The number surpassed our model's estimate of $2.37 billion. Analytical Instruments Revenues in this segment (15.9%) declined 3% year over year to $1.73 billion. The figure missed our model's estimate of $1.84 billion. Specialty Diagnostics Revenues in the Specialty Diagnostics segment (10.4%) increased 1.5% year over year to $1.13 billion. The number missed our model's prediction of $1.15 billion. Laboratory Products and Biopharma Services Revenues in this segment (55.2%) rose 4.1% year over year to $5.99 billion. Our model's estimate was $5.71 billion. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) TMO's Margin Performance Gross margin of 41.2% in the second quarter contracted 83 basis points (bps) year over year due to a 4.4% increase in the cost of revenues. In the quarter, selling, general and administrative expenses rose 5.4% to $1.78 billion. Research and development expenses increased 3.8% to $352 million. The adjusted operating margin in the quarter was 21.6%, reflecting a contraction of 124 bps. Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise TMO's Financial Position The company ended the second quarter of 2025 with cash and cash equivalents and short-term investments of $6.39 billion compared with $5.95 billion at the end of the first quarter of 2025. Cumulative net cash from operating activities at the end of the second quarter was $2.12 billion compared with $3.21 billion a year ago. Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth of 14.86%. Our Take on Thermo Fisher Stock Thermo Fisher exited the second quarter of 2025 with better-than-expected results, wherein both earnings and revenues beat the respective estimates. Barring the Analytical Instruments segment, all other business segments reported growth during the quarter. However, contraction of both margins in the quarter was discouraging. The company will provide its 2025 guidance on the earnings call today. During the second quarter, the company advanced in its growth strategy by launching a range of next-generation, high-impact, innovative instruments, including the Thermo Scientific Orbitrap Astral Zoom mass spectrometer, the Thermo Scientific Orbitrap™ Excedion Pro mass spectrometer and the Thermo Scientific Krios 5 Cryo-TEM. These instruments help researchers deepen the understanding of complex diseases, advance precision medicine and enable the development of new therapies. In addition, TMO expanded the DynaDrive single-use bioreactor portfolio for drug production to include a new first-of-its-kind bench-scale system, enabling meaningful workflow efficiencies and seamless scale-up from the bench to commercialization. All these developments translated into meaningful commercial wins for the company in the second quarter, which is encouraging. TMO's Zacks Rank & Key Picks Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Veeva Systems VEEV and Boston Scientific BSX. Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. You can see the complete list of today's Zacks #1 Rank stocks here. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Veeva Systems, currently carrying a Zacks Rank #2 (Buy), reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Boston Scientific, carrying a Zacks Rank #2 at present, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report
